Granite Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Granite Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21,710	Closed	-$8.91M	–	367
2019 Q1	$8.91M	Buy	21,710 +481	+2%	+$198K	0.51%	80
2018 Q4	$7.93M	Buy	21,229 +8,831	+71%	+$3.23M	0.58%	74
2018 Q3	$5.01M	Buy	+12,398	New	+$4.72M	0.29%	104
2014 Q1	–	Sell	-9,473	Closed	-$2.61M	–	270
2013 Q4	$2.61M	Sell	9,473 -296	-3%	-$85.1K	0.4%	73
2013 Q3	$3.06M	Sell	9,769 -275	-3%	-$72.3K	0.5%	71
2013 Q2	$2.26M	Buy	+10,044	New	+$2.34M	0.4%	87

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Granite Investment Partners's REGN Position: Q2 2019 in Review

Granite Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 21,710 shares — an estimated $8.91M sold.

Granite Investment Partners first reported a position in REGN in Q2 2013 and held it in 6 quarters. The position peaked at $8.91M in Q1 2019. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

Granite Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Granite Investment Partners sold 21,710 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $8.91M.
Granite Investment Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Granite Investment Partners's Regeneron Pharmaceuticals position peaked at $8.91M in Q1 2019.
658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Granite Investment Partners's 13F filing for Q2 2019, filed 7 Aug 2019.